Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AARP Will Continue Pricing Dialogue With Manufacturers; Website Planned

Executive Summary

AARP will launch its own pharmaceutical price comparison website in conjunction with the rollout of the Medicare-endorsed discount card program

You may also be interested in...



AARP “Rx Watchdog” Tracking Price Increases Ahead of Medicare Benefit

An upcoming AARP "Rx Watchdog" study will analyze price increases enacted by manufacturers in the first quarter of 2004 heading into the launch of the Medicare drug discount card program

AARP “Rx Watchdog” Tracking Price Increases Ahead of Medicare Benefit

An upcoming AARP "Rx Watchdog" study will analyze price increases enacted by manufacturers in the first quarter of 2004 heading into the launch of the Medicare drug discount card program

Medicare Rx Discount Card Sponsors Expect To Beat CMS’ Savings Estimate

Medicare drug discount card sponsors appear confident that they will be able to provide savings in excess of CMS' projection of 10% to 15%

Related Content

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel